Epsilon, an Alliance Data (NYSE: ADS) company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society® (LLS) the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.
Under the renewal agreement, Epsilon will continue to host and manage LLS's constituent database for multi-channel communications efforts aimed at further engaging donors, patients and advocates. Epsilon's constituent database provides timely and actionable data that enables LLS to execute society-wide marketing initiatives that connect with constituents in a more personal, consistent, and relevant manner across multiple communications channels.
In addition, Epsilon will now also provide comprehensive marketing campaign management focused on driving greater stakeholder constituent participation in fundraising and advocacy efforts across all communications channels and giving. Through marketing database segmentation and developing consumer profiles, Epsilon will deliver a more holistic, 360-degree view of LLS constituents, providing LLS with a more effective and efficient means to communicate across all LLS programs.
"Epsilon understands consumers and knows the right channels to use to communicate to our constituents. The innovative data technology that Epsilon provides will enable us to better engage with our constituents and clients in a more targeted manner," said Lisa Stockmon, chief marketing officer, LLS.
"The Leukemia & Lymphoma Society and Epsilon have enjoyed a successful partnership for over 15 years. We understand that data is essential for driving results and engaging The Leukemia & Lymphoma Society's target base in a more relevant and consequential way," said Bryan Kennedy, Chief Executive Officer of Epsilon. "I am confident that Epsilon will continue to deliver measurable results, and deliver direct marketing performance capabilities and results that will benefit LLS in building lifetime constituent engagement. Together, we will assist LLS in managing and expanding their marketing programs and relationships now and in the years to come."
Leukemia cells depend on P-bodies for growth and survival